More articles from Supplement

Transplant innovation and ethical challenges: What have we learned?
Denton A. Cooley, MD, John J. Fung, MD, PhD, James B. Young, MD, Thomas E. Starzl, MD, PhD, Mark Siegler, MD and Pauline W. Chen, MD
Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S24-S32;
Preface
Lawrence K. Altman, MD
Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S61;
We have come far, but selecting organ recipients remains an ethical minefield
Denton A. Cooley, MD
Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S24-S25;
A device company perspective: Serving patients is the key to sustainable success
Michael A. Mussallem
Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S61-S62;
Despite the odds, the transplant field has progressed rapidly
John J. Fung, MD, PhD
Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S25-S26;
A regulatory and legal perspective: Issues in off-label device use
Rebecca Dresser, JD
Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S63-S64;
The pathogenesis of gout
Brian F. Mandell, MD, PHD and H. Ralph Schumacher, MD
Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S2-S4;
Clinical manifestations of hyperuricemia and gout
Brian F. Mandell, MD, PhD
Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S5-S8;
Epidemiology of gout
Brian F. Mandell, MD, PHD and Arthur L. Weaver, MD, MS
Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S9-S12;
The role of hyperuricemia and gout in kidney and cardiovascular disease
Brian F. Mandell, MD, PHD and N. Lawrence Edwards, MD
Cleveland Clinic Journal of Medicine July 2008, 75 (7 suppl 5) S13-S16;

Pages